Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Alnylam Pharmaceuticals (NASDAQ:ALNY)

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s (NASDAQ:ALNY) supplemental application for Amvuttra (vutrisiran). The drug treats adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. ATTR-CM is a rare heart condition where a protein called transthyretin (T…

FDA Expands Approval for Alnylam’s Drug to Treat Rare Heart Disease - The Thinking Conservative

FDA approved Alnylam’s drug to treat a rare and deadly heart disease, allowing entry of new type of medicine in a market dominated by Pfizer’s Vyndaqel. The post FDA Expands Approval for Alnylam’s Drug to Treat Rare Heart Disease appeared first on The Thinking Conservative.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by JPMorgan Chase & Co.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Monday, MarketBeat.com reports. The firm presently has a $328.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $280.00. […]

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s (NASDAQ:ALNY) supplemental application for Amvuttra …

FDA Approves Vutrisiran For Adult Patients With ATTR-CM

The decision makes the RNAi therapeutic the only therapy approved by the FDA to treat ATTR-CM and hATTR-PN.